Join Creoptix and Dr. Michael Hennig, CEO at leadXpro, at the Drug Discovery Chemistry (in-person event) in San Diego (US).
Our session on Tuesday 19th April 2022 - 03:15-03:30pm PST will discuss:
Biophysical methods are instrumental for characterization of ligand-target interactions to maximize the success of structure determination by EM and X-ray facilitating the design of optimized molecules. leadXpro implemented Grating-Coupled Interferometry (GCI) to measure affinity, stoichiometry and kinetic parameters.
In the talk from Dr. Michael Hennig, case studies of small molecule-GPCR (e.g. CCR2, A2B) and -ion channel (e.g. TRPV4) interaction studies are presented as well as binding studies of synthetic nanobodies raised against membrane protein targets.
About the conference
Fragment-based drug discovery (FBDD) continues to be a fruitful approach for many biophysical and medicinal chemists when initiating screening campaigns to arrive at new small molecule drug leads. Fragment libraries as opposed to typical small molecule libraries are proving especially useful against targets that are often difficult for small molecules to bind, such as flatter and larger targets without good pockets like many protein-protein interaction (PPI) targets. Often the fragment hits highlight new chemical space to be explored for growing the fragment into a drug lead. However it’s usually not as simple as it sounds.
Join us to share and discuss strategies and challenges with fellow FBDD practitioners in biopharma and academics.
Creoptix and Dr. Michael Hennig, CEO at leadXpro
- Session on Tuesday 19th April 2022 - 03:15-03:30pm PST
- In-person: Hilton San Diego Bayfront, 1 Park Boulevard, San Diego, CA 92101
- Plus virtual
Who should attend?
- Medicinal and biophysical chemists working in pharma, biotech, and academia